Method 1 In method la, water (10 mL) and concentrated HC (1 mL) were added to meconium
(1 g). The mixture wa vortex-mixed, filtered, and centrifuged. The supernatant was analyzed for opiate and cocaine metabolites by enzyme-multiplied immunoassay technique (EMIT). In method ib, methanol (0.4 mL) was added to meconium (0.1 g), mixed, and left at room temperature fo 10 mm. The mixture was centrifuged and analyzed b EMIT for cannabinoids (2).
Method 2 To meconium (1 g), 5 mL of 0.1 molfL phosphate buffer-methanol (4:1) were added. The mixture was centrifuged and filtered, and the supernatant was analyzed by EMIT for amphetamines, cannabinoids, cocaine, and opiate metabolites.
The screening cute values for methods 1 and 2 were 50 .tgfL, as recommended in the literature (3).
Method 3
Meconium (1 g) was homogenized in glacial acetic acid (3 mL). Diphenylamine in acetone (1.67 mgfL; 6 mL) was added, and the resultant solution was mixed and centrifuged.
The top layer was evaporated to dryness (a drop of 1% H2S04 was added to prevent amphetamine loss). The sample was reconstituted in Abbott AD5 buffer-methanol (50:50; 0.7 mL) and centrifuged.
The The goal of the meconium test is to provide the clinician with an accurate fetal drug exposure history; therefore, sensitivity is of primary importance.
A sensitive screen assay sacrifices specificity; therefore, a specific con.firinatory procedure is necessary. Such an approach does not lend itself to reporting screen-only results. Healthcare professionals should be aware of the possible consequences that may arise from such diagnoses.
